Back to Browse Journals » Clinical Epidemiology » Volume 3 » Issue 1

Physical activity and mortality among Norwegian women – the Norwegian Women and Cancer Study

Authors Borch KB, Braaten T, Lund E, Weiderpass E

Published Date July 2011 Volume 2011:3(1) Pages 229—235

DOI http://dx.doi.org/10.2147/CLEP.S22681

Published 29 July 2011

Kristin Benjaminsen Borch1, Tonje Braaten1, Eiliv Lund1, Elisabete Weiderpass1,2,3,4
1Department of Community Medicine/University of Tromsø, Tromsø, Norway; 2Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 3Cancer Registry of Norway, Oslo, Norway; 4Folkhälsan Research Centre, Samfundet Folkhälsan, Helsinki, Finland

Background: Physical activity (PA) and its relationship with all-cause mortality suggest a strong and consistent inverse association. This study prospectively investigated the association between PA level and mortality among participants of the Norwegian Women and Cancer (NOWAC) Study.
Methods: A total of 66,136 NOWAC participants were followed-up until December 31st 2008. PA level and possible confounding factors were obtained through a self-administered questionnaire at enrolment. Cox proportional hazards regression was used to calculate adjusted relative risks (RRs) and 95% confidence intervals (CIs) for all-cause, cardiovascular disease (CVD) and cancer mortality and PA levels defined from 1 to 10 on a global scale.
Results: PA levels 1–4 were associated with a significantly increased risk of all-cause mortality (level 1 RR = 2.35; 95% CI: 1.94–2.84, level 2 RR = 1.71; 95% CI: 1.45–2.00, level 3 RR = 1.30; 95% CI: 1.14–1.49, level 4 RR = 1.07; 95% CI: 0.95–1.22), compared with PA level 5. CVD mortality risk increased in PA levels 1–3 (level 1 RR = 3.50; 95% CI: 2.41–5.10, level 2 RR = 1.50; 95% CI: 0.99–2.25, level 3 RR = 1.12; 95% CI: 0.79–1.60) as did cancer mortality risk (RR = 1.32; 95% CI: 0.96–1.81, RR = 1.48; 95% CI: 1.19–1.84, RR = 1.26; 95% CI: 1.06–1.50, respectively). The magnitude of the associations was consistent across strata of age, smoking, and body mass index. The population attributable fractions for PA levels 1–4 were: all-cause mortality, 11.5%; CVD mortality, 11.3%; cancer mortality, 7.8%.
Conclusion: There is a significant trend of increased risk of all-cause, CVD and cancer mortality in relation to low PA levels among Norwegian women.

Keywords: physical activity, mortality, cardiovascular disease, cancer, Norway, women

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Imiglucerase in the treatment of Gaucher disease: a history and perspective

Deegan PB, Cox TM

Drug Design, Development and Therapy 2012, 6:81-106

Published Date: 18 April 2012

Validation and verification of the OPI 2.0 System

Abelson R, Lane KJ, Rodriguez J, Johnston P, Angjeli E, Ousler G, Montgomery D

Clinical Ophthalmology 2012, 6:613-622

Published Date: 24 April 2012

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

Dejager S, Schweizer A, Foley JE

Vascular Health and Risk Management 2012, 8:339-348

Published Date: 18 May 2012

Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD

Hareendran A, Leidy NK, Monz BU, Winnette R, Becker K, Mahler DA

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:345-355

Published Date: 28 May 2012

Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells

Matsuo H, Yoshimoto N, Iijima M, Niimi T, Jung J, Jeong SY, Choi EK, Sewaki T, Arakawa T, Kuroda S

International Journal of Nanomedicine 2012, 7:3341-3350

Published Date: 3 July 2012

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, Awad AG, Keefe RS, Naber D

Patient Preference and Adherence 2012, 6:521-532

Published Date: 13 July 2012